IQVIA (NYSE:IQV) Lowered to Hold Rating by Wall Street Zen

IQVIA (NYSE:IQV) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also weighed in on IQV. Jefferies Financial Group cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Citigroup lowered their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Truist Financial lowered their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. Finally, Morgan Stanley set a $240.00 price objective on IQVIA in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $226.63.

IQVIA Price Performance

Shares of IQVIA stock opened at $167.49 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The business has a 50-day moving average price of $173.38 and a 200 day moving average price of $204.03. The firm has a market cap of $28.42 billion, a PE ratio of 21.31, a P/E/G ratio of 1.63 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the previous year, the business earned $3.12 EPS. IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts predict that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameliora Wealth Management Ltd. acquired a new position in IQVIA in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the last quarter. International Assets Investment Management LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $27,000. Finally, CrossGen Wealth LLC acquired a new position in IQVIA in the fourth quarter valued at approximately $28,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.